Prostate Cancer | Specialty

Recognizing the Role of Bias in Patient Decision Making

November 19th 2014

Doctors are taught to think through medical decisions by listing a series of options, weighing the risks and benefits of each, and ultimately concluding on the superior option. This comparative maximization approach is drilled into us as medical students and residents.

Dr. Sweeney on the Future of Prostate Cancer Research

November 18th 2014

Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses the future of prostate cancer research.

Sipuleucel-T Maker Dendreon Files for Bankruptcy

November 10th 2014

Dendreon, the maker of the first FDA-approved immunotherapy for advanced prostate cancer, sipuleucel-T (Provenge), has filed for chapter 11 bankruptcy.

Bayer Restores Access to Radium-223 for Prostate Cancer

November 6th 2014

Access to radium-223 dichloride has been restored following a temporary suspension in production by its manufacturer Bayer HealthCare Pharmaceuticals to adjust its manufacturing process to meet certain quality standards that the company has in place.

Chasing CTCs: Novel Technologies May Unlock Potential of Elusive Biomarker

October 28th 2014

Despite being discovered more than 150 years ago, tumor cells present in the blood of patients with cancer are only now inspiring significant research efforts. Technological advancements have allowed the isolation and enrichment of these rare cells and, as potential metastatic "emissaries," they have significant potential for improving the detection and treatment of advanced and possibly even early-stage disease.

Novel Drugs Are Being Studied in GU Cancers

October 25th 2014

A round-up of new drugs that are being investigated as treatments for genitourinary cancers.

Game Changers in Prostate Cancer

October 23rd 2014

Over the past 6 months, we have had two studies that will profoundly affect our management of advanced prostate cancer patients.

How Test Reimbursement Decisions Are Made: A Leader of Medicare's MolDX Program Discusses Evaluation Process

October 21st 2014

Despite the promise associated with biomarker-based tools as a means of helping to guide cancer diagnosis and treatment, there is a potential stumbling block: insurance reimbursement.

Treatment Selection in Metastatic Prostate Cancer

October 16th 2014

Convincing Long-Term Survival With Abiraterone in mCRPC

October 16th 2014

Quality of Life and Survival With Abiraterone in CRPC

October 16th 2014

Researchers Discuss Novel Therapies in NSCLC

October 16th 2014

Latest News & Insight: October 16, 2014

October 16th 2014

Radium-223 Production Halted Due to Manufacturing Glitch

October 15th 2014

Production of the prostate cancer drug radium-223 has been temporarily suspended by its maker, Bayer HealthCare Pharmaceuticals, due to a manufacturing problem.

Advancing Prostate Cancer Care

October 12th 2014

The prostate cancer team at the Comprehensive Cancer Center at Wake Forest Baptist Medical Center has recently focused on two primary areas: minimally invasive care and clinical research.

Dr. Antonarakis on AR-V7 and Resistance to AR-Targeting Agents in mCRPC

October 8th 2014

Emmanuel S. Antonarakis, MBBCh, assistant professor, Johns Hopkins Medicine, discusses AR-V7 and resistance to AR-targeting agents in men with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Fernandez Discusses Immunotherapy Plus Radiation Therapy for Prostate Cancer

October 6th 2014

Eduardo Fernandez, MD, PhD, FACRO, Senior Vice President, Medical Affairs / Medical Director for Latin America, Radiation Oncologist, 21st Century Oncology, discusses the potential for immunotherapy and radiation therapy to be used together to treat prostate cancer.

Hopkins Researcher Discusses AR-V7 and Resistance to AR-Targeting Agents

October 4th 2014

Androgen receptor splice variant-7 (AR-V7) is a truncated form of the AR that does not have the ligand-binding domain. Detection of AR-V7 in circulating tumor cells (CTCs) can be used to predict resistance to AR-targeting agents, such as abiraterone or enzalutamide.

Vogelzang Disputes 'Weak' Guideline Rating for Sipuleucel-T

October 3rd 2014

In a recent guideline for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC), the American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO) shared their thoughts on the implementation of six drugs approved since their previous recommendations were issued in 2007, as well as on older drugs.

New Data Provide Insight Into Optimal Pre-Chemo Treatments for mCRPC

September 30th 2014

The combination of abiraterone acetate and prednisone has demonstrated a statistically significant improvement in overall survival (OS) for men with metastatic castration-resistant prostate cancer (mCRPC) who had not received prior treatment with chemotherapy